1988
DOI: 10.1016/0160-5402(88)90031-9
|View full text |Cite
|
Sign up to set email alerts
|

Improved oral dosing technique for rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2004
2004
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(14 citation statements)
references
References 0 publications
0
14
0
Order By: Relevance
“…Oral gavage with 1.5 g/kg of glucose was performed followed by glucose testing at baseline (before the gavage) and 20, 60, and 90 minutes after the gavage as described by Conybeare and Leslie. 14 A drop of blood was then obtained from the tip of the tail and glucose was measured using a glucometer on site (True Track Smart System; Home Diagnostic Inc., Fort Lauderdale, FL).…”
Section: Methodsmentioning
confidence: 99%
“…Oral gavage with 1.5 g/kg of glucose was performed followed by glucose testing at baseline (before the gavage) and 20, 60, and 90 minutes after the gavage as described by Conybeare and Leslie. 14 A drop of blood was then obtained from the tip of the tail and glucose was measured using a glucometer on site (True Track Smart System; Home Diagnostic Inc., Fort Lauderdale, FL).…”
Section: Methodsmentioning
confidence: 99%
“…Micro-aspiration of the protein-containing test solution or vagally mediated reflex bronchospasms due to the gavage could lead to the observed changes (Conybeare and Leslie, 1988). There also may be an association between gastro-esophageal reflux and an accumulation of alveolar macrophages (Nussbaum et al, 1987).…”
Section: Subchronic (13-week) Oral Toxicity In Ratsmentioning
confidence: 99%
“…Based on their anatomy, rats are non‐emetic obligate nose breathers (Takeda et al ., 1993), and there is no clear anatomical path for food or the dosing formulation to flow back up and exit via the mouth. As a result, reflux during gavage dosing can result in subsequent back flow of the compound formulation into the nasal cavity and aspiration into the respiratory tract (Conybeare and Leslie, 1988). An inability to clearly differentiate gavage‐related effects from compound‐related toxicity in the first‐in‐human enabling nonclinical studies, can lead to substantial delays in starting clinical phase 1 studies, limitations in dose escalation to pharmacological targets and even program termination.…”
Section: Introductionmentioning
confidence: 99%